STAGE IB-IIIA NSCLC

Clinical trials for STAGE IB-IIIA NSCLC explained in plain language.

Never miss a new study

Get alerted when new STAGE IB-IIIA NSCLC trials appear

Sign up with your email to follow new studies for STAGE IB-IIIA NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New triple therapy targets hard-to-treat lung cancer before surgery

Disease control Recruiting now

This study tests a new approach for people with a certain genetic lung cancer (KRAS G12C mutation) that can be removed with surgery. Before surgery, patients receive a targeted pill (fulzerasib) for 6 weeks, then a 2-week break, followed by 3 cycles of immunotherapy (sintilimab) …

Matched conditions: STAGE IB-IIIA NSCLC

Phase: PHASE2 • Sponsor: Jianxing He • Aim: Disease control

Last updated May 11, 2026 20:51 UTC

STAGE IB-IIIA NSCLC

Get alerted when new STAGE IB-IIIA NSCLC trials appear

New triple therapy targets hard-to-treat lung cancer before surgery